PUBLISHER: Allied Market Research | PRODUCT CODE: 1140254
PUBLISHER: Allied Market Research | PRODUCT CODE: 1140254
The global intravenous solutions market was valued at $11,857.7 million in 2021, and is projected to reach $26,558.4 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.
IV solutions are specially formulated liquids that are injected into a vein to prevent or treat dehydration. They are used in people of all ages who are sick, injured and dehydrated from exercise, heat and those who are undergoing surgery. Intravenous rehydration is a simple, safe and common procedure with a low risk of complications. They are injected into a person's veins through an IV (intravenous) tube. They prevent or treat dehydration and electrolyte imbalances. There are two types of intravenous fluids that include, crystalloid solutions and colloids. Crystalloid solutions contain small dissolved molecules that pass easily from the bloodstream into tissues and cells. Some of the examples of it include normal saline, which is salt in water, and D5W, which is dextrose (sugar) in water. Moreover, lactated Ringer's, which contains sodium, chloride, potassium, calcium and lactate can also be included in the crystalloid solutions. Colloids are large molecules that can't easily pass through cell membranes and are more likely to stay in the blood vessels. Some of the examples include albumin and hetastarch solutions.
The global intravenous solutions market is anticipated to show significant market growth during the forecast period, owing to increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population. Furthermore, increase in prevalence of cancer and rise in natality rate are considerably contributing toward the market growth. However, lack of experienced healthcare professionals and complications of intravenous administration therapy are negatively impacting the market growth. Conversely, the high growth opportunities in emerging markets offers the lucrative opportunities for the growth of the market.
The intravenous solutions market is segmented on the basis of type, composition, end user, and region. By type, the market is classified into partial parenteral nutrition and total parenteral nutrition. Furthermore, the partial parenteral nutrition is sub-classified as pediatric and adult. Also, the total parenteral nutrition is sub-classified as pediatric and adult. By composition, the market is classified into carbohydrates, vitamins and minerals, single dose amino acids, parenteral lipid emulsion and others. By end user, the market is classified into hospitals and clinics, ambulatory surgery centers, home care settings. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, Taiwan and Rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Venezuela, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in the report include: Amanta Healthcare Ltd., Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd, Fresenius Kabi AG, Grifols S.A., Henry Schein Inc., ICU Medical, Inc., JW Life Science, OtsUKa Pharmaceutical Co.,Ltd., Pfizer, Inc., Salius Pharma Private Limited , Sichuan Kelun Pharmaceutical Co. Ltd., Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd.
Key Benefits For Stakeholders
Key Market Segments
By Type
By Composition
By End Users
By Region